Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID

Cerno Bioscience announced today that it has released version 1.1 of its innovative MassWorks Rx GC/ID software. GC/ID is a fully automated data processing software that enables dramatic improvements for GC/MS qualitative analysis. By incorporating Cerno’s proven TrueCal™ calibration technology for accurate mass formula ID along with conventional NIST library search, a significant improvement in compound ID certainty is achieved on single quad GC/MS systems. GC/ID also provides an entirely automated method of quantitatively utilizing the NIST retention index values to provide yet a third orthogonal metric for compound ID. Finally, a powerful new approach is used to identify and deconvolve mixtures and the background of co-eluting peaks to minimize the misidentification of compounds in complex samples.

Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID

The software can be set up to automatically process an entire sequence of GC/MS runs from most vendor instruments including the popular Agilent GC/MSD. An entire run can be analyzed in a few minutes including spectral and chromatogram peak calibration, peak picking/deconvolution, and subsequent analysis of every peak by NIST search, accurate mass/spectral accuracy formula ID, retention index fit, and final report generation. The three metrics can be “blended” into a new overall match quality or used independently to deliver dramatic compound ID improvements and valuable time savings.  

New in V1.1 is the ability to perform accurate mass/spectral accuracy identification of the major fragment ions as well as the molecular ion. This further improves the confidence of compound ID.  GC/ID can now use calculated retention time index values to extend the retention time libraries for compounds in the NIST or user libraries. Further improvements have also been made to the powerful peak deconvolution algorithms and report generation is now more flexible than ever.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerno Bioscience. (2020, March 09). Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID. AZoLifeSciences. Retrieved on November 24, 2024 from https://www.azolifesciences.com/news/20200309/Cerno-Bioscience-releases-GCID-V11-software-for-highly-confident-GCMS-compound-ID.aspx.

  • MLA

    Cerno Bioscience. "Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID". AZoLifeSciences. 24 November 2024. <https://www.azolifesciences.com/news/20200309/Cerno-Bioscience-releases-GCID-V11-software-for-highly-confident-GCMS-compound-ID.aspx>.

  • Chicago

    Cerno Bioscience. "Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID". AZoLifeSciences. https://www.azolifesciences.com/news/20200309/Cerno-Bioscience-releases-GCID-V11-software-for-highly-confident-GCMS-compound-ID.aspx. (accessed November 24, 2024).

  • Harvard

    Cerno Bioscience. 2020. Cerno Bioscience releases GC/ID V1.1 software for highly confident GC/MS compound ID. AZoLifeSciences, viewed 24 November 2024, https://www.azolifesciences.com/news/20200309/Cerno-Bioscience-releases-GCID-V11-software-for-highly-confident-GCMS-compound-ID.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.